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OBJECTIVE—Fixed genomic variation explains only a small
proportion of the risk of adiposity. In animal models, maternal
diet alters offspring body composition, accompanied by epige-
netic changes in metabolic control genes. Little is known about
whether such processes operate in humans.
RESEARCH DESIGN AND METHODS—Using Sequenom
MassARRAY we measured the methylation status of 68 CpGs 59
from ﬁve candidate genes in umbilical cord tissue DNA from
healthy neonates. Methylation varied greatly at particular CpGs:
for 31 CpGs with median methylation $5% and a 5–95% range
$10%, we related methylation status to maternal pregnancy diet
and to child’s adiposity at age 9 years. Replication was sought in
a second independent cohort.
RESULTS—In cohort 1, retinoid X receptor-a (RXRA) chr9:
136355885+ and endothelial nitric oxide synthase (eNOS) chr7:
150315553+ methylation had independent associations with
sex-adjusted childhood fat mass (exponentiated regression coef-
ﬁcient [b] 17% per SD change in methylation [95% CI 4–31], P =
0.009, n = 64, and b = 20% [9–32], P , 0.001, n = 66, respectively)
and %fat mass (b =1 0 %[ 1 –19], P = 0.023, n =6 4a n db =12% [4–20],
P = 0.002, n = 66, respectively). Regression analyses including
sex and neonatal epigenetic marks explained .25% of the var-
iance in childhood adiposity. Higher methylation of RXRA chr9:
136355885+, but not of eNOS chr7:150315553+, was associated
with lower maternal carbohydrate intake in early pregnancy, pre-
viously linked with higher neonatal adiposity in this population. In
cohort 2, cord eNOS chr7:150315553+ methylation showed no as-
sociation with adiposity, but RXRA chr9:136355885+ methylation
showed similar associations with fat mass and %fat mass (b =6 %
[2–10] and b =4 %[ 1 –7], respectively, both P = 0.002, n = 239).
CONCLUSIONS—Our ﬁndings suggest a substantial component
of metabolic disease risk has a prenatal developmental basis.
Perinatal epigenetic analysis may have utility in identifying
individual vulnerability to later obesity and metabolic disease.
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F
ixed genomic variations explain only a fraction
of the risk of human obesity and metabolic dis-
ease (1,2). However, there is increasing epide-
miological evidence linking perinatal factors to
later adiposity and metabolic disease risk (3,4). For ex-
ample, famine during pregnancy is associated with obesity
in the adult offspring (5) and normal variations in maternal
body composition relate to child’s later adiposity (6). Al-
though understanding of the underlying mechanisms is
limited, data from animal models suggest that epigenetic
processes are an important link between the early life en-
vironment, for example maternal diet, and altered metabo-
lism and body composition in the adult offspring (7–9).
Epigenetic processes such as DNA methylation and
histone modiﬁcations allow the developmental environ-
ment to modulate gene transcription; many of these
changes are then stable throughout the lifecourse (10,11).
Regulated DNA methylation mostly occurs at a cytosine
immediately 59 to a guanine (CpG sites). Such processes
are involved not only in cell differentiation and parental
genomic imprinting but also in developmental plasticity
through which the environment in early life can affect the
developmental trajectory, with long-term effects on gene
expression and phenotypic outcome (12–14). For example,
in the rat unbalanced maternal diet during pregnancy
induces changes in DNA methylation and covalent histone
modiﬁcations in the 59 regulatory regions of speciﬁc non-
imprinted genes (15–17) and affects the offspring’s later
body composition and metabolic phenotype. Induced
changes in phenotype can be prevented by nutritional
interventions during pregnancy (18), or altered by nutri-
tional interventions during the juvenile-pubertal period
(19) or by hormonal interventions during suckling (20).
Although epigenetic processes operating in early de-
velopment have been implicated in the origins of obesity
(3,11), there is as yet no direct evidence for this proposi-
tion in humans. Furthermore, there has been considerable
debate as to the relative importance of such developmental
pathways in determining phenotypic outcomes. Any asso-
ciation between epigenetic state at birth and later pheno-
type would allow an estimate of the possible developmental
contribution, irrespective of whether such an association
was causal or simply reﬂected the developmental state.
We reasoned that the targeted measurement of DNA
methylation in human fetal tissues at birth might not only
provide evidence that environmental inﬂuences have af-
fected prenatal development but, if they then correlated
with later phenotype, would provide an approach to
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ORIGINAL ARTICLEdemonstrating the role of the prenatal environment in
predisposition to adiposity.
Here we ﬁrst measured the methylation status of CpGs
in the promoters of candidate genes in DNA extracted
from umbilical cord tissue obtained at birth in children
who were later assessed for adiposity at age 9 years (the
Princess Anne Hospital [PAH] study) (21). Measurements
of perinatal DNA methylation were related to adiposity in
later childhood and to information on mother’s diet during
pregnancy. Because of the strong associations found, we
then sought to replicate associations between umbilical
cord CpG methylation and child’s adiposity in a second
independent group of children from the Southampton
Women’s Survey (SWS) (22).
RESEARCH DESIGN AND METHODS
We studied two prospective cohorts recruited antenatally in Southampton, U.K.
In the PAH study, Caucasian women $16 years old with singleton pregnancies
,17 weeks’ gestation were recruited and a validated food frequency ques-
tionnaire (23) was administered at 15 weeks’ gestation; patients with diabetes
and hormonally induced conceptions were excluded. When the children
approached 9 years, we wrote to 461 still living locally. Two hundred and
sixteen (47%) attended a clinic, and adiposity was measured using dual energy
X-ray absorptiometry (DEXA); 78 had DNA available from an umbilical cord
sample collected at birth and stored at 280°C. None of the mothers were
administered glucocorticoids during pregnancy.
In the SWS, women aged 20–34 years were recruited when not pregnant;
those who subsequently conceived were followed through pregnancy and the
offspring followed up (22). To replicate associations with adiposity found in
the PAH cohort, we studied 239 children selected as having both umbilical
cord DNA available and childhood adiposity measurements.
Both groups underwent adiposity measurement by DEXA (PAH study, age
9years:LunarDPX-L,pediatricsoftware,version4.7c;GECorporation,Madison,
WI [6]; SWS, age 6 years: Hologic Discovery, pediatric scan mode; Hologic,
Bedford, MA). Instruments were calibrated daily; coefﬁcients of variation were
,1%. Follow-up of the children and sample collection/analysis was carried out
under Institutional Review Board approval (Southampton and SW Hampshire
Research Ethics Committee) with written informed consent. Investigations
were conducted according to the principles expressed in the Declaration of
Helsinki.
Selection of candidate genes. DNA from 15 randomly selected PAH study
umbilical cords underwent methylation-speciﬁc chromatin precipitation fol-
lowed by hybridization to a commercial tiled oligomer microarray (NimbleGen
Systems HG17_min_promoter array [24]), which uses 50-mer oligonucleotides
positioned on average every 100 bp from 23,750 bp to +500 bp relative to the
transcription start site of 24,134 human genes. We focused our analysis ini-
tially on a panel of 78 candidate genes, 28 selected on the basis of animal data
from our and other laboratories (25,26) and 50 selected from the array as
having the highest SD between subjects relative to the SD of within-subject
replicates. For this panel we identiﬁed those with correlations between overall
gene methylation status and DEXA measurements of adiposity at age 9 years
and from these genes chose ﬁve genes for further study based on individual
oligomers showing evidence of correlation with DEXA measurements at age
9 years, biological plausibility and feasibility of designing amplicons suitable
for Sequenom analysis; genes selected were retinoid X receptor-a (RXRA),
endothelial nitric oxide synthase (eNOS), superoxide dismutase-1 (SOD1),
interleukin-8 (IL8), and phosphoinositide-3-kinase, catalytic, d-polypeptide
(PI3KCD). These genes all had associations of comparable strength between
childhood body composition and both overall gene promoter methylation
and the methylation of individual oligomers. All chromosomal coordinates
are based on University of California Santa Cruz, human genome March 2006
assembly (hg18).
Sequenom and single nucleotide polymorphism analysis. Genomic DNA
was puriﬁed from frozen cords by proteinase K digestion and phenol:chloroform
extraction. DNA methylation was measured with the Sequenom MassARRAY
Compact System (www.sequenom.com/). Brieﬂy, gene-speciﬁca m p l i ﬁcation
of bisulﬁte-treated DNA was followed by in vitro transcription and analysis
by matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry (27,28). Sequenom assay design and methods were as per the
manufacturer’sp r o t o c o l .D N A( 1mg) was bisulﬁte converted using EZ DNA
Methylation kit (Zymo Research). PCR primers speciﬁc for bisulﬁte con-
verted DNA were designed (Methprimer). Each reverse primer contained a
T7-promoter tag for in vitro transcription (59-cagtaatacgactcactatagggagaaggct-39),
and the forward primer was tagged with a 10mer to balance Tm (59-aggaagagag-39).
Supplementary Table 1 lists amplicons, primer sequences, PCR annealing
temperature, and genomic coordinates for the extended promoter regions
measured. Bisulﬁte-treated DNA was PCR ampliﬁed (Qiagen HotStar Taq
Polymerase) in 5 mL reactions and treated with Shrimp Alkaline Phosphatase
(Sequenom) (20 min at 37°C), heat inactivated (85°C for 5 min), and simulta-
neous in vitro transcription/uracil-cleavage reaction was carried out (7 mL
reactions) using Sequenom T-cleavage reagent mix. Transcription cleavage
products were desalted with 6 mg of Clean-Resin and 20 nL spotted on a 384-pad
SpectroCHIP (Sequenom) using a MassARRAY nanodispenser (Samsung). Mass
spectra were acquired using a MassARRAY MALDI-TOF MS (Bruker-Sequenom)
and peak detection, signal-to-noise calculations, and quantitative CpG site
methylation performed using proprietary EpiTyper software v1.0 (Sequenom).
Consistent with the manufacturer’ss p e c i ﬁcation (www.sequenom.com) agree-
ment between technical replicates was good, duplicate measures differing by
,10% methylation in almost all cases. We excluded from analysis samples that
failed to give a reliable PCR product or produced spectra with low conﬁdence
scores (,2.9 in EpiTyper). For fragments containing a single CpG site, DNA
methylation was calculated by the ratio of methylated to unmethylated frag-
ments. Limitations imposed by Sequenom analysis treat cleavage products
containing multiple CpG sites as single units, and the methylation values
reported are weighted averages across the unit (referred to as a CpG group).
DNA quality and no-template controls, 0%, and 100% methylated DNA were
included in all assays. Supplementary Table 2 shows the distributions of meth-
ylation values for CpGs and CpG groups and numbers of subjects with mea-
surements available.
Pyrosequencing analysis (PyroMark Q96MD; Qiagen) was undertaken to
exclude single nucleotide polymorphisms (SNPs) involving CpG dinucleotides,
which would result in loss of potential for methylation. Brieﬂy, DNA was PCR
ampliﬁed, and the product annealed to streptavidin-coated sepharose beads
and denatured (0.2M NaOH) to a single-stranded product. Nucleotides were
incorporated to the open 39 DNA strand in which pyrophosphate is released
and used in a sulfurylase reaction emitting ATP, measured in a luciferase re-
action, and analyzed using PyroMark MD v1.0 software (Qiagen) (29).
Statistical analysis. Using Stata 11 (StataCorp) study variables were trans-
formed using Fisher-Yates (30) (for methylation measurements) or logarithmic
transformations where necessary to satisfy statistical assumptions of nor-
mality. A priori we restricted the analysis to CpGs with median methylation
$5% and a 5–95% range $10%. In PAH subjects we ﬁrst used Pearson corre-
lation (rp) and linear regression to examine CpG methylation in relation to
child’s adiposity. Mutually adjusted regression models were built including
CpG sites signiﬁcantly associated with each outcome in univariate analyses
(P , 0.05). Because the measurements of childhood adiposity are on the log
scale and the CpG measurements are z scores, the exponentiated results are
interpreted as percent change in childhood adiposity measurements per SD
change in methylation. To allow assessment of the inﬂuence of taking account
of the child’s sex, exponentiated regression coefﬁcients are ﬁrst presented
excluding and including adjustment for child’s sex. We then preadjusted all
adiposity measurements for sex and took account of the mother’s age, adi-
posity (as continuous variables), and smoking during pregnancy (as a binary
variable, yes/no) by including them as covariates in the regression model; we
next related mother’s diet to CpG methylation at birth. Finally, we sought
replication of the associations between CpG methylation and child’s adiposity
in the SWS cohort. SWS measurements, taken over a wider age range than
those in PAH subjects, were preadjusted for age and sex.
RESULTS
Median (interquartile range) birth weight, age, fat mass,
and %body fat at follow-up values for the PAH subjects
were 3,330 g (3,010–3,790), 8.66 years (8.52–8.73), 5.41 kg
(3.97–8.41), and 18.3% (14.4–27.0), respectively. Compara-
ble values for the 239 SWS children were 3,485 g (3,205–
3,773), 6.59 years (6.41–6.78), 4.60 kg (3.66–5.69), and 23.4%
(19.7–27.6), respectively. Similar percentages of mothers
smoked in the PAH and SWS cohorts (21 vs. 24%, respec-
tively); median maternal age and prepregnancy BMI were
lower in the PAH mothers (28 vs. 31 years and 22.3 vs. 24.3
kg/m
2, respectively). The above characteristics are similar to
the overall values for participants in the two cohorts.
PAH cohort methylation studies. Supplementary Table
2 shows the distribution of percent methylation of the 68
CpGs and CpG groups among the 78 PAH subjects; 31
CpGs/CpG groups met a priori criteria for further analysis.
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methylation was seen at some sites (for example, RXRA
chr9:136355885+ had a median of 59% with 5–95th centiles
4–99%; eNOS chr7:150315553+ had a median of 93%, with
5–95th centiles 64–100%). Correlations between methyla-
tion of different CpGs were generally low (for example
rp= 20.03, P = 0.81, n = 55 between the above two CpGs).
Of the 31 CpGs with variable methylation above the
a priori threshold, seven had signiﬁcant associations with
the child’s adiposity at age 9 years (Supplementary Table
3). Table 1 shows the results of uni- and multivariate
analyses of CpG sites with signiﬁcant independent asso-
ciations with the child’s adiposity. Comparison of the re-
gression coefﬁcients for the univariate and multivariate
associations of RXRA chr9:136355885+ and eNOS chr7:
150315553+ methylation with child’s fat mass, %fat, and
ratio of trunk to limb fat shows that mutual adjustment for
each other and sex has little effect on the coefﬁcients;
adiposity measurements were therefore preadjusted for
sex in further analyses. RXRA chr9:136355885+ methyla-
tion had positive associations with childhood fat mass,
%fat mass (scatterplots shown in Supplementary Fig. 1),
and ratio of trunk to limb fat, with similar positive asso-
ciations for eNOS chr7:150315553+: exponentiated re-
gression coefﬁcients (b) (95% CI) per SD change in
methylation were 17% (4–31), P = 0.009; 10% (1–19), P =
0.023; and 6% (0–12), P = 0.039, respectively (n =6 4 ) .
Comparable values for eNOS chr7:150315553+ methylation
were 20% (9–32), P , 0.001; 12% (4–20), P = 0.002; and 7%
(2–13), P = 0.007, respectively (n = 66). Methylation of RXRA
chr9:136355885+ and eNOS chr7:150315553+ had similar
positive associations with child’sB M I( b =3 %[ 0 –6], P =
0.037; and 4% [2–7], P = 0.001, respectively). Independently of
RXRA chr9:136355885+ and eNOS chr7:150315553+ methyl-
ation, SOD1 chr21:31853660/63+ methylation was also in-
versely related to child’s trunk-to-limb fat ratio (P =0 . 0 3 7 ) .
The associations reﬂect clinically important shifts in adipos-
ity such that the mean fat mass rose from 4.8 kg (17.3% body
fat) in the lowest quarter of RXRA chr9:136355885+ methyl-
ation to 6.6 kg (21.3% body fat) in the highest quarter of
the distribution. Taking account of RXRA chr9:136355885+
methylation and sex explained 26% of the variance in fat mass
in PAH children, and simultaneous analyses showed that the
association between RXRA chr9:136355885+ methylation and
child’s fat mass was not attenuated after adjustment for birth
weight and mother’s age, smoking, and BMI.
In this population we have previously linked lower
maternal carbohydrate intake in early pregnancy with
higher neonatal adiposity (21). Relating umbilical cord CpG
methylation to maternal carbohydrate intake in early
pregnancy, higher methylation of RXRA chr9:136355885+,
but not of eNOS chr7:150315553+, was associated with a
lower maternal carbohydrate intake (Fig. 1). The mother’s
early pregnancy fat and protein intakes in early pregnancy
were not associated with cord RXRA chr9:136355885+
methylation (P = 0.7 and P = 0.6, respectively), and no
additional variance in RXRA chr9:136355885+ methylation
was explained by simultaneously taking account of ma-
ternal fat and protein intakes in early pregnancy or mac-
ronutrient intakes in late pregnancy. Relating umbilical
cord CpG methylation to the infant’s size at birth, only
three CpGs showed a signiﬁcant correlation with birth
weight adjusted for sex and gestational age (PIK3CD
chr1:9609980+ [rp= 20.32, P = 0.013, n = 58], PIK3CD
chr1:9635676/79+ [rp= 20.36, P = 0.028, n = 37], and SOD1
chr 21:31853827+ [rp= 20.27, P = 0.029, n = 65]). RXRA
chr9:136355885+ methylation showed a weak association
with the subjects’ sex and age-adjusted height (rp= 0.24,
P = 0.054) but was not associated with the infant’s weight
or ponderal index at birth.
Methylation analysis in the SWS cohort. We next
sought to replicate the stronger associations found in the ﬁrst
cohort (eNOS chr7:150315553+ and RXRA chr9:136355885+
CpG methylation and child’s adiposity) in the SWS cohort
(20). In these 239 SWS children, eNOS chr7:150315553+
showed no association with adiposity, but RXRA chr9:
136355885+ showed remarkably similar and statistically
signiﬁcant associations (fat mass, b =6 %[ 2 –10], P =0 . 0 0 2 ;
%fat mass, b =4 %[ 1 –7], P =0 . 0 0 2 ,b o t hn =2 3 9 )t ot h o s e
in PAH children. As in the PAH cohort, these associations
were little changed after taking account of birth weight
and maternal age, smoking, and BMI. Figures 2 and 3 show
the graded associations between cord RXRA chr9:136355885+
methylation and child’s fat mass and %fat mass in the two
cohorts.
Pyrosequencing across RXRA chr9:136355885+ in SWS
subjects showed no C allele SNPs that could account for
differences in methylation observed between individuals.
TABLE 1
Univariate and multivariate analyses of umbilical cord CpG methylation in relation to child’s adiposity measured by DEXA at age
9 years
eNOS
chr7:150315553+ (%) P
RXRA
chr9:136355885+ (%) P Sex (%) P
Variance
explained (%)
Total fat mass (ln kg)
Univariate analysis 21 0.001 21 0.003 39 0.001
Multivariate analysis 19 0.002 23 0.001 47 0.001 44
Percentage fat (ln %)
Univariate analysis 13 0.006 14 0.006 42 ,0.001
Multivariate analysis 11 0.009 14 0.005 48 ,0.001 47
Ratio trunk to limb fat (ln)
Univariate analysis 7 0.008 7 0.016 12 0.009
Multivariate analysis 8 0.004 7 0.021 11 0.059 28
Values are the percent change in outcome variable per SD change in CpG methylation and P value. Univariate analysis rows show the regression
coefﬁcients and P values relating each of eNOS chr7:150315553+, RXRA chr9:136355885+, and sex to outcomes individually, whereas multi-
variate analysis rows show regression coefﬁcients and P values for a combined analysis of eNOS chr7:150315553+, RXRA chr9:136355885+, and
sex in relation to outcomes, together with the variance explained by the multivariate model. For variances explained, n =5 5 .
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This study provides novel evidence for the importance of
the developmental contribution to later adiposity. We
found that greater methylation of RXRA chr9:136355885+
measured at birth was strongly correlated with greater
adiposity in later childhood in two independent cohorts.
Although we studied a subset of children in both cohorts
these were selected on the basis of subject and specimen
availability, so it is unlikely that selection bias could ex-
plain the relationships observed unless the association
between RXRA methylation and adiposity was different in
the remainder of the cohort. The data build on animal
experiments suggesting that the developmental environ-
ment acts through epigenetic processes to exert a strong
inﬂuence on postnatal body composition and metabolic
function (7–11).
Our study shows that speciﬁc components of the epi-
genetic state at birth predict later childhood adiposity. The
associations with adiposity were linked to speciﬁc CpGs 59
to the start site of the selected candidate genes. Although
some of the CpGs studied were either within the proximal
promoter or close to it, others were more distal and may
be exerting effects through the regulation of other genes.
Nevertheless the data indicate possible mechanistic path-
ways, suggesting avenues for future study. Our observation
that adjacent or nearby CpGs within the same promoter
showed differences in the strength of association with
child’s adiposity suggests highly speciﬁcc h a n g e si nt h e
transcriptional regulation of these genes induced by the
developmental environment, rather than generalized changes
in promoter methylation. Both CpG hyper- (eNOS chr7:
150315553+ and RXRA chr9:136355885+) and hypometh-
ylation (SOD1 chr21:31853660/63+) at different sites were
associated with body fat distribution, again indicating com-
plexity in transcriptional control. The speciﬁcity of the
associations between methylation of an individual CpG and
both maternal diet and child’s phenotype endorses the
concept of a ﬁne control of development by environmental
factors via epigenetic processes.
Our observation indicates one potential mechanistic
pathway involved, because induction of transcription by
RXRA is dependent on its binding to ligands including the
peroxisome proliferator–activated receptors, involved in
insulin sensitivity, adipogenesis, and fat metabolism (31,32).
Moreover, RXRA chr9:136355885+ is located in a region
considered to contain positive regulatory elements of tran-
scription (33). Figure 4 shows the proximity of RXRA
chr9:136355885+ to proposed binding sites for RXR, MAF,
NF-kB, and AP1. Retinoid receptor biology is complex, and
increased RXRA methylation might be acting through a
variety of pathways (34); however, an association between
increased RXRA methylation and adiposity is consistent
with the observation of strongly diminished RXRA expres-
sion in visceral white adipose tissue from obese mice (35).
Moreover, a role for retinoid receptor methylation in de-
velopmental inﬂuences on later metabolic risk is supported
by recent experimental data showing an inﬂuence of ma-
ternal diet during pregnancy on methylation of LXRA, a
heterodimeric partner of RXRA (36).
Genome-wide association studies suggest that ﬁxed ge-
netic variation makes a relatively small contribution to risk
of obesity, heart disease, and diabetes (1,2); our ﬁndings
raise the possibility that the developmental environment
component may be equally or more important. We excluded
FIG. 1. Lower maternal carbohydrate in early pregnancy is associated
with higher umbilical cord RXRA chr9:136355885+ methylation in the
PAH cohort. Values are means + SEM.
FIG. 2. Child’s %fat mass and fat mass at age 9 years increase with higher umbilical cord RXRA chr9:136355885+ methylation in the PAH cohort.
Values are means + SEM. *Fat mass and percentage fat mass are preadjusted for sex.
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quencing, but without genome-wide analysis it is not pos-
sible to exclude a genetic effect of distant SNPs, which
could inﬂuence both DNA methylation of a particular se-
quence and child’s phenotype. However, even if this were
the case, our data clearly indicate that epigenetic measures
at birth may have prognostic value. Although epigenetic
changes can be dynamic, experimental studies have shown
that environmental factors acting on the genotype during
development relate to epigenetic proﬁle in adulthood (7,15),
and there are longitudinal human studies showing that DNA
methylation is often stable over time (37). Such changes can
be tissue speciﬁc, and in this respect the umbilical cord may
be advantageous because it contains a high proportion of
fetal vascular tissue and mesenchymal cells, which may be
relevant to later adiposity. Furthermore, unlike the placenta
it is a tissue in which consistency of sampling between
individuals is more likely. Although experimental work in
the rat suggests that methylation changes induced by ma-
ternal diet can be similar in the umbilical cord and liver
(38), further work is needed to determine the relevance of
epigenetic changes in human umbilical cord tissue. Recent
data show that for some genomic regions methylation
appears largely independent of tissue of origin, whereas
for others there is a clear tissue-speciﬁc dependence (39).
Many epidemiological studies have shown associations
between fetal development, through the proxy measure of
birth size, and later adiposity and metabolic function (3,4),
but the developmental contribution to such phenotypic
characteristics has remained uncertain and controversial.
This study provides the ﬁrst estimate of the developmental
contribution to phenotype associated with human disease
risk based on measures of the underpinning biology: our
data for RXRA chr9:136355885+ suggest that a substantial
proportion of the variation in adiposity in prepubertal
children can be explained by epigenetic measurements
made at birth. Although our data are correlative and thus
can only imply an association between DNA methylation at
birth and later phenotype, the importance of the observa-
tion stands irrespective of whether the RXRA methylation is
causally related to the development of adiposity. Even if it
is simply a noncausal association, the changed epigenetic
FIG. 4. Schematic diagram of the RXRA promoter region, showing the position of the CpG group at RXRA chr9:136355885+ (underlined) and of
neighboring transcription factor binding sites.
FIG. 3. In a second independent cohort, child’s %fat mass and fat mass at age 6 years increase with higher umbilical cord RXRA chr9:136355885+
methylation in SWS subjects. Values are means + SEM. *Fat mass and percentage fat mass are preadjusted for age and sex.
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mental trajectory by the time of birth. Despite the limitations
of dietary intake assessment tools, the instrument we used is
both validated and provides information that can be used to
rank the nutrient intakes of individuals (23).
Methylation of eNOS chr7:150315553+ was associated
with later adiposity in the initial cohort only. This may
reﬂect a chance ﬁnding, or different maternal character-
istics in the two cohorts, such as the greater maternal
adiposity and maternal folate supplementation in the SWS
cohort (22,40,41). Alternatively, adipocyte proliferation is
high during the ﬁrst year of life but then remains low until
a second proliferative phase from age 9–14 years (42).
Thus the processes that determine adiposity at age 9 years
might differ from those at age 6 years. Nitric oxide syn-
thesis by eNOS promotes preadipocyte differentiation
(43). Therefore, a further possible explanation is that
eNOS methylation in umbilical cord marks capacity for
adipogenesis which has a greater net contribution to adi-
posity at age 9 years than age 6 years.
Our ﬁndings show strong associations between epige-
netic markers and childhood total and central body fat.
Beyond these simple associations, multivariate analysis
indicates that the associations explain substantial pro-
portions of the variances in outcomes, emphasizing an
important developmental contribution to phenotypes asso-
ciated with metabolic dysfunction and disease risk. It is
noteworthy that the genes for which we report effects are
not imprinted. In vitro fertilization increases risk of im-
printing disorders (44), and methylation effects on imprinted
genes have been reported in offspring of mothers exposed
to famine during various periods of pregnancy (45,46), but
with no associations with phenotype reported. The current
study implicates the human prenatal environment with
epigenetic changes in nonimprinted genes and is the ﬁrst
to link epigenetic status at birth with clinically relevant
later phenotypic variation.
Variation in the degree of methylation of nonimprinted
genes and in later cardiovascular and metabolic physiol-
ogy can be induced experimentally by manipulation of the
developmental environment, for example by altering ma-
ternal nutrition or administering glucocorticoids during
pregnancy (8,9), often without necessarily affecting the
birth size of the offspring. Although we found associations
between some epigenetic markers and birth weight, these
were weaker associations than those with later phenotype
and were for different markers; moreover, previous reports
on the same cohort showed only modest associations be-
tween birth weight and later body composition (6). Because
birth weight in humans is inﬂuenced by multiple factors
including the mother’s own birth weight and height and by
gestational length (40), epigenetic changes may provide a
more sensitive index than birth weight of environmentally
induced effects on fetal development.
There are potentially important implications of the strong
and replicated association between RXRA chr9:136355885+
methylation and later adiposity. First, the effect is consid-
erably greater than that of factors such as birth weight or
maternal body composition, suggesting that epigenetic
measurements made in the neonate may be useful pre-
dictors of later obesity and other phenotypic outcomes.
Second, the association between CpG methylation and
child’s adiposity operates within the normal ranges of
maternal nutritional state and birth size; this supports the
argument that developmental programming is the conse-
quence of an evolved and potentially adaptive process
involving the mechanisms of developmental plasticity (10).
Indeed the data provide strong evidence supporting a role
for developmental plasticity in determining individual risk
of metabolic disease. Third, the data suggest that devel-
opmental factors may be more signiﬁcant in contributing to
phenotypic variation and disease risk than generally consid-
ered. Fourth, the association between RXRA chr9:136355885+
methylation and mother’s carbohydrate intake raises the
possibility that conditions in early pregnancy could affect
child’s adiposity through this pathway. This provides
additional support for the argument that all women of re-
productive age should have appropriate nutritional, educa-
tion, and lifestyle support to improve the health of the next
generation. Finally, our data suggest that epigenetic mea-
sures at birth may have prognostic value and potential utility
for monitoring programs to optimize maternal health and
nutrition for long-term beneﬁts to the offspring; however,
evaluation of this possibility will require further research
correlating methylation measu r e m e n t si ne a r l yl i f ew i t h
those in later life.
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